Skip to main content
AstraZeneca PLC logo

AstraZeneca PLC — Investor Relations & Filings

Ticker · AZN ISIN · GB0009895292 LEI · PY6ZZQWO2IZFZC3IOL08 IL Manufacturing
Open in API
Filings indexed 3,304 across all filing types
Latest filing 2026-01-30 Foreign Filer Report
Country GB United Kingdom
Listing IL AZN

About AstraZeneca PLC

https://www.astrazeneca.com/

AstraZeneca PLC is a global, science-led biopharmaceutical company that focuses on the discovery, development, and commercialization of prescription medicines. The company's portfolio is concentrated on several main therapy areas, including Oncology; Cardiovascular, Renal & Metabolism; and Respiratory & Immunology. AstraZeneca is committed to advancing healthcare through a robust research and development pipeline, aiming to deliver innovative medicines that address significant unmet medical needs for millions of patients worldwide. The company leverages scientific innovation to transform the future of healthcare and improve patient outcomes.

Recent filings

Filing Released Lang Actions
6-K Filing
Foreign Filer Report
2026-01-30 English
25 Filing
Delisting Announcement
2026-01-30 English
AstraZeneca invests $15bn in China through 2030
Regulatory Filings Classification · 1% confidence The document is an official announcement from AstraZeneca regarding a $15 billion investment in China. It is distributed via the Regulatory News Service (RNS) of the London Stock Exchange. While it discusses corporate strategy and investment, it does not fit into specific categories like '10-K' (annual report), 'CT' (transcript), or 'IP' (presentation). As it is a general corporate announcement regarding business operations and strategic investment, it falls under the 'RNS' (Regulatory Filings) category as the fallback for general regulatory announcements.
2026-01-29 English
6-K Filing
Foreign Filer Report
2026-01-29 English
AstraZeneca to complete direct listing on NYSE
Regulatory Filings Classification · 1% confidence The document is an official announcement from AstraZeneca regarding the voluntary withdrawal of its listing from Nasdaq and its subsequent direct listing on the New York Stock Exchange (NYSE). While it involves a change in listing venue, it does not constitute a full delisting from all exchanges (as it is moving to the NYSE) nor is it a standard share issue. Given the nature of the announcement regarding exchange listing status, it falls under the category of general regulatory announcements provided via RNS.
2026-01-20 English
6-K Filing
Foreign Filer Report
2026-01-20 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.